* Many erring officials enjoy prime postings Mohinder Verma JAMMU, Apr 22: Notwithstanding explicit directions from the High Court and numerous reminders from the General Administration Department, 21 Government departments are reluctant to ... Daily Excelsior.com, 9 hours ago
3 images for "arun sawhney"
The Indian auto market has a bright future in spite of the unprecedentedly prolonged phase of recession being currently witnessed. This was the message that emerged in no uncertain terms from the deliberations at Auto Summit 2014 held in New Delhi ...MotorIndia, 1 day ago
In the drug business, the arrival of generic competition usually means falling prices as rivals rush to win market share for medicines whose patents have expired. Then there's Diovan from Novartis This patent-law quirk has expensive consequences ...BusinessWeek, 5 days ago Heart Drug Costs $900 Million More as Generic Held Back: Health Washington Post, 1 week ago Ranbaxy's Woes Add $900 Million to U.S. Heart Drug Costs Bloomberg, 1 week ago Ranbaxy's woes add $900 million in costs for heart drug Livemint.com, 1 week ago
Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility is currently banned from supplying products ...Business Standard India, 1 week ago
More from: , Smart Investor...and 1 other sources
Indian pharmaceutical firm Ranbaxy Laboratories has struggled ever since its promoter family sold controlling interest in the company to Japan's Daiichi Sankyo in 2008. No one, however, expected the Japanese pharma major to give up the fight. In an ...Wharton, 1 week ago Sun Pharma buys Ranbaxy for $3.2b, turns it Indian again The Financial Chronicle, 2 weeks ago Sun Pharma buys Ranbaxy to create generics giant Livemint.com, 2 weeks ago Sun Pharma to buy Ranbaxy in $3.2B all-stock deal VC Circle, 2 weeks ago
DAIICHI SANKYO : Announcement Regarding Merger Between Sun Pharma and Daiichi Sankyo's Subsidiary Ranbaxy and Resulting Change in Subsidiary
For Immediate Release 2014.04.11 Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate ...4 Traders, 1 week ago Ranbaxy: Lessons and Opportunities PharmaceuticalProcessing, 1 week ago Top heads to roll soon at Ranbaxy Business Standard India, 1 week ago Sun Pharma to acquire Ranbaxy The Hindu, 2 weeks ago
Mumbai: On hindsight, which is always 20:20, the stock movement in the preceding week should have foretold the story. On Friday, 4 April, shares of Ranbaxy Laboratories Ltd rose 8.2% to Rs. 459.55 on BSE, taking the stock's weekly gain to 26%. ...Livemint.com, 1 week ago
NEW DELHI: A senior-level exit has taken place at Ranbaxy Laboratories, after Chairman Tsutomu Une, a veteran at Japanese parent Daiichi Sankyo, held an open house meeting to introspect on what went wrong with the company and who should be held ...Economic Times, 2 weeks ago Ranbaxy's TL Easwar quits post introspection Economic Times, 2 weeks ago
The move is seen as enhancing the company's global presence Sushmi Dey | New Delhi April 8, 2014 Last Updated at 00:25 IST Sun Pharma’s acquisition of Ranbaxy has once again revived evaluation of the troubled past of the latter, which had ...Business Standard India, 2 weeks ago
T 1: Achieving Compliance With the baggage of regulatory issues, the biggest challenge for Sun Pharma will be to restore and regain trust and confidence of the regulators, especially in the US. Four of Ranbaxy plants are banned by USFDA and is ...Moneycontrol.com, 2 weeks ago 5 challenges for Sun in Ranbaxy deal | Shanghvi, pharma maven with midas touch Economic Times, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!